



## Regeneron Genetics Center

Regeneron Genetics Center (RGC) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics. The primary goal of RGC is to improve patient outcomes by identifying novel drug targets, clinical indications for development programs, and genomic biomarkers for pharmacogenomic applications.

## Therapeutic Areas of Interest



Oncology



Cardiovascular



Metabolic



Musculoskeletal



Ophthalmology



Infectious Diseases



Respiratory Diseases



Immune Diseases



Founder & Special Populations



Neurology

“RGC applies the best and latest technologies in sequencing and analytics to harness the power of human genetics to create game changing new medicines.” – Aris Baras, Head of RGC

## RGC Milestones

- 2013** Regeneron sought to further explore the human genetic code and RGC was born. Launched foundational initiative with Geisinger to sequence 100k participants.
- 2017** Discovered inhibition of ANGPTL3 gene in humans and mice is associated with decreased levels of all 3 major lipid fractions and protection from atherosclerotic cardiovascular disease.
- 2018** Uncovered loss-of-function variant in HSD17B13 gene associated with reduced risk of chronic liver disease. Partnered with UK Biobank to accelerate our research goals.
- 2020** Sequenced our 1,000,000th exome – first organization in the world to do so.
- 2021** Discovered rare genetic mutations in GPR75 gene associated with protection against obesity.
- 2022** Uncovered a novel association between rare mutations in the CIDEA gene and protection from liver damage and disease.
- 2023** 10-year anniversary of RGC's founding.
- 2024** Validated whole exome sequencing approach with peer-reviewed publication.
- 2025** Launched collaboration with Truveta to sequence up to 10 million de-identified patient volunteers. Initiated world's most comprehensive study of proteins with UK Biobank and biopharma partners.

## Science - Led

World-class scientists & researchers.

**250+**

publications authored  
based on RGC data

**1<sup>st</sup>**

organization  
to sequence 1 million exomes

## RGC Collaborations

Global network of collaborator institutions.

**150+**

collaborations

**~30**

countries

## The Database

Largest & most diverse in the world.

**2.7M+**

exomes sequenced  
and counting

**650K+**

underrepresented  
individuals sequenced

## Development of Therapeutics

Our mission: genetics to therapeutics, designed for all.

**6**

genetics medicines  
programs in the clinic

**~30**

therapeutic programs started  
from novel RGC targets or known  
genes with novel RGC insights

**25+**

novel genetic  
targets discovered

**50+**

novel protective  
genetics discoveries

Science Obsessed, Human Inspired.